Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial

Lancet

Volumn 368, Issue 9540, 2006, Pages 991-997

  Lin, Jiangtao ^a   Zhang, Jiansan ^b   Dong, Xiaoping ^c   Fang, Hanhua ^e   Chen, Jiangting ^b   Su, Nan ^a   Gao, Qiang ^b   Zhang, Zhenshan ^b   Liu, Yuxuan ^b   Wang, Zhihong ^a   Yang, Meng ^a   Sun, Ruihua ^a   Li, Changgui ^e   Lin, Su ^b   Ji, Mei ^b   Liu, Yan ^b   Wang, Xu ^b   Wood, John ^f   Feng, Zijian ^d   Wang, Yu ^d   Yin, Weidong ^b   more..

^a Chinese Japanese Friendship Hospital   (China)

^b Sinovac Biotech Co Ltd   (China)

^c National Institute for Viral Disease Control and Prevention   (China)

^d CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^e NATIONAL INSTITUTE FOR THE CONTROL OF PHARMACEUTICAL AND BIOLOGICAL PRODUCTS   (China)

^f NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; ANTIGEN; HEMAGGLUTININ; INACTIVATED VACCINE; INFLUENZA VACCINE; PLACEBO;

ADULT; ANTIBODY RESPONSE; ARTHRALGIA; ARTICLE; BIOASSAY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG FEVER; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FATIGUE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA VIRUS A; INJECTION SITE PAIN; INJECTION SITE SWELLING; MYALGIA; NAUSEA; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SERUM; SKIN INDURATION; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; VIRION; VIRUS INHIBITION; VIRUS NEUTRALIZATION;

EID: 33748447102     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(06)69294-5     Document Type: Article

References (26)

1. CDC. Avian influenza: current situation. http://www.cdc.gov/flu/avian/outbreaks/current.htm (accessed Aug 17, 2006)
2. WHO. Cumulative number of confirmed human cases of avian influenza A (H5N1) reported to WHO. http://www.who.int/csr/disease/avian_influenza/country/cases_table_2006_08_23/en/index.html (accessed Aug 23, 2006)
3. Ungchusak K., Auewarakul P., Dowell S., et al. Probable person-to-person transmission of avian influenza A (H5N1). N Engl J Med 352 (2005) 333-340
4. The World Health Organization Global Influenza Program Surveillance Network. Evolution of H5N1 avian influenza viruses in Asia. Emerg Infect Dis 11 (2005) 1515-1521
5. WHO. Responding to the avian influenza pandemic threat: recommended strategic actions. http://www.who.int/csr/resources/publications/influenza/WHO_CDS_CSR_GIP_05_8-EN.pdf (accessed Aug 17, 2006)
6. Wood J. Selection of influenza vaccine strains and developing pandemic vaccines. Vaccine 20 (2002) B40-B44
7. Stephenson I., Gust I., Kieny M., and Pervikov Y. Development and evaluation of influenza pandemic vaccines. Lancet Infect Dis 6 (2006) 71-72
8. Chinese State Food and Drug Administration (SFDA). Special procedure for drug approval. No 21, 2005.
9. Treanor J., Campbell J., Zangwill K., Rowe T., and Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 354 (2006) 1343-1351
10. Bresson J., Perronne C., Launay O., et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 367 (2006) 1657-1664
11. Nicholson K., Colegate A., Podda A., et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 357 (2001) 1937-1943
12. Hehme N., Engelmann H., Kunzel W., Neumeier E., and Sanger R. Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines. Med Microbiol Immunol 191 (2002) 203-208
13. Nicholson K., Tyrrell D., Harrison C., et al. Clinical studies of monovalent inactivated whole virus and subunit A/USSR/77 (H1N1) vaccine: serological responses and clinical reactions. J Biol Stand 7 (1979) 123-136
14. Stephenson I., Nicholson K., Gluck R., et al. Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial. Lancet 362 (2003) 1959-1966
15. Hehme N., Engelmann H., Kuenzel W., Neumeier E., and Saenger R. Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use. Virus Res 103 (2004) 163-171
16. Wood J., and Robertson J. From lethal virus to life-saving vaccine: developing inactivated vaccines for pandemic influenza. Nat Rev Microbiol 2 (2004) 842-847
17. Division of Microbiology and Infectious Diseases. Adult toxicity table. http://www.niaid.nih.gov/dmid/clinresearch/dmidadulttoxtable.doc (accessed Aug 25, 2006)
18. Kendal A., Pereira M., and Skehel J. Concepts and procedures for laboratory based influenza surveillance (1982), WHO, Geneva, Switzerland
19. Reed L., and Muench H. A simple method of estimating fifty percent endpoints. Am J Hyg 27 (1938) 493
20. European Committee for Proprietary Medicinal Products. Note for guidance on harmonization of requirements for influenza vaccines, March 1997 (CPMP/BWP/214/96). http://www.emea.eu.int/pdfs/human/bwp/021496en.pdf (accessed Aug 25, 2006)
21. Wright P., Thompson J., Vaughn W., Folland D., Sell S., and Karzon D. Trials of influenza A/New Jersey/76 virus vaccine in normal children: an overview of age-related antigenicity and reactogenicity. J Infect Dis 136 (1977) S731-S741
22. WHO. Development and evaluation of influenza pandemic vaccines: report of WHO expert meeting. Initiative for Vaccine Research, Global Influenza Programme. http://www.who.int/vaccine_research/documents/Report%20021105.pdf (accessed Aug 17, 2006)
23. Cintra O., and Rey L. Safety, immunogenicity and efficacy of influenza vaccine in children. J Pediatr (Rio J) 82 (2006) S83-S90
24. WHO. Communicable disease surveillance and response. http://www.wpro.who.int/sites/csr/data/data_Graphs.htm (accessed July 17, 2006)
25. al-Mazrou A., Scheifele D., Soong T., and Bjornson G. Comparison of adverse reactions to whole-virion and split-virion influenza vaccines in hospital personnel. CMAJ 145 (1991) 213-218
26. Gross P., Ennis F., Gaerlan P., Denson L., Denning C., and Schiffman D. A controlled double-blind comparison of reactogenicity, immunogenicity, and protective efficacy of whole-virus and split-product vaccines in children. J Infect Dis 136 (1977) 623-632